View in EDS PDF Full Text

Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood-brain barrier integrity.

Saved in:
Bibliographic Details
Title: Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood-brain barrier integrity.
Authors: Hammer, C, Stepniak, B, Schneider, A, Papiol, S, Tantra, M, Begemann, M, Sirén, A-L, Pardo, L A, Sperling, S, Mohd Jofrry, S, Gurvich, A, Jensen, N, Ostmeier, K, Lühder, F, Probst, C, Martens, H, Gillis, M, Saher, G, Assogna, F, Spalletta, G
Source: Molecular Psychiatry. Oct2014, Vol. 19 Issue 10, p1143-1149. 7p.
Subjects: Psychoses, Autoimmunity, Autoimmune diseases, Methyl aspartate receptors, Schizophrenia treatment, Blood-brain barrier disorders
Abstract: In 2007, a multifaceted syndrome, associated with anti-NMDA receptor autoantibodies (NMDAR-AB) of immunoglobulin-G isotype, has been described, which variably consists of psychosis, epilepsy, cognitive decline and extrapyramidal symptoms. Prevalence and significance of NMDAR-AB in complex neuropsychiatric disease versus health, however, have remained unclear. We tested sera of 2817 subjects (1325 healthy, 1081 schizophrenic, 263 Parkinson and 148 affective-disorder subjects) for presence of NMDAR-AB, conducted a genome-wide genetic association study, comparing AB carriers versus non-carriers, and assessed their influenza AB status. For mechanistic insight and documentation of AB functionality, in vivo experiments involving mice with deficient blood-brain barrier (ApoE−/−) and in vitro endocytosis assays in primary cortical neurons were performed. In 10.5% of subjects, NMDAR-AB (NR1 subunit) of any immunoglobulin isotype were detected, with no difference in seroprevalence, titer or in vitro functionality between patients and healthy controls. Administration of extracted human serum to mice influenced basal and MK-801-induced activity in the open field only in ApoE−/− mice injected with NMDAR-AB-positive serum but not in respective controls. Seropositive schizophrenic patients with a history of neurotrauma or birth complications, indicating an at least temporarily compromised blood-brain barrier, had more neurological abnormalities than seronegative patients with comparable history. A common genetic variant (rs524991, P=6.15E−08) as well as past influenza A (P=0.024) or B (P=0.006) infection were identified as predisposing factors for NMDAR-AB seropositivity. The >10% overall seroprevalence of NMDAR-AB of both healthy individuals and patients is unexpectedly high. Clinical significance, however, apparently depends on association with past or present perturbations of blood-brain barrier function. [ABSTRACT FROM AUTHOR]
Copyright of Molecular Psychiatry is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 98712667
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood-brain barrier integrity.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Hammer%2C+C%22">Hammer, C</searchLink><br /><searchLink fieldCode="AR" term="%22Stepniak%2C+B%22">Stepniak, B</searchLink><br /><searchLink fieldCode="AR" term="%22Schneider%2C+A%22">Schneider, A</searchLink><br /><searchLink fieldCode="AR" term="%22Papiol%2C+S%22">Papiol, S</searchLink><br /><searchLink fieldCode="AR" term="%22Tantra%2C+M%22">Tantra, M</searchLink><br /><searchLink fieldCode="AR" term="%22Begemann%2C+M%22">Begemann, M</searchLink><br /><searchLink fieldCode="AR" term="%22Sirén%2C+A-L%22">Sirén, A-L</searchLink><br /><searchLink fieldCode="AR" term="%22Pardo%2C+L+A%22">Pardo, L A</searchLink><br /><searchLink fieldCode="AR" term="%22Sperling%2C+S%22">Sperling, S</searchLink><br /><searchLink fieldCode="AR" term="%22Mohd+Jofrry%2C+S%22">Mohd Jofrry, S</searchLink><br /><searchLink fieldCode="AR" term="%22Gurvich%2C+A%22">Gurvich, A</searchLink><br /><searchLink fieldCode="AR" term="%22Jensen%2C+N%22">Jensen, N</searchLink><br /><searchLink fieldCode="AR" term="%22Ostmeier%2C+K%22">Ostmeier, K</searchLink><br /><searchLink fieldCode="AR" term="%22Lühder%2C+F%22">Lühder, F</searchLink><br /><searchLink fieldCode="AR" term="%22Probst%2C+C%22">Probst, C</searchLink><br /><searchLink fieldCode="AR" term="%22Martens%2C+H%22">Martens, H</searchLink><br /><searchLink fieldCode="AR" term="%22Gillis%2C+M%22">Gillis, M</searchLink><br /><searchLink fieldCode="AR" term="%22Saher%2C+G%22">Saher, G</searchLink><br /><searchLink fieldCode="AR" term="%22Assogna%2C+F%22">Assogna, F</searchLink><br /><searchLink fieldCode="AR" term="%22Spalletta%2C+G%22">Spalletta, G</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Molecular+Psychiatry%22">Molecular Psychiatry</searchLink>. Oct2014, Vol. 19 Issue 10, p1143-1149. 7p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Psychoses%22">Psychoses</searchLink><br /><searchLink fieldCode="DE" term="%22Autoimmunity%22">Autoimmunity</searchLink><br /><searchLink fieldCode="DE" term="%22Autoimmune+diseases%22">Autoimmune diseases</searchLink><br /><searchLink fieldCode="DE" term="%22Methyl+aspartate+receptors%22">Methyl aspartate receptors</searchLink><br /><searchLink fieldCode="DE" term="%22Schizophrenia+treatment%22">Schizophrenia treatment</searchLink><br /><searchLink fieldCode="DE" term="%22Blood-brain+barrier+disorders%22">Blood-brain barrier disorders</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: In 2007, a multifaceted syndrome, associated with anti-NMDA receptor autoantibodies (NMDAR-AB) of immunoglobulin-G isotype, has been described, which variably consists of psychosis, epilepsy, cognitive decline and extrapyramidal symptoms. Prevalence and significance of NMDAR-AB in complex neuropsychiatric disease versus health, however, have remained unclear. We tested sera of 2817 subjects (1325 healthy, 1081 schizophrenic, 263 Parkinson and 148 affective-disorder subjects) for presence of NMDAR-AB, conducted a genome-wide genetic association study, comparing AB carriers versus non-carriers, and assessed their influenza AB status. For mechanistic insight and documentation of AB functionality, in vivo experiments involving mice with deficient blood-brain barrier (ApoE−/−) and in vitro endocytosis assays in primary cortical neurons were performed. In 10.5% of subjects, NMDAR-AB (NR1 subunit) of any immunoglobulin isotype were detected, with no difference in seroprevalence, titer or in vitro functionality between patients and healthy controls. Administration of extracted human serum to mice influenced basal and MK-801-induced activity in the open field only in ApoE−/− mice injected with NMDAR-AB-positive serum but not in respective controls. Seropositive schizophrenic patients with a history of neurotrauma or birth complications, indicating an at least temporarily compromised blood-brain barrier, had more neurological abnormalities than seronegative patients with comparable history. A common genetic variant (rs524991, P=6.15E−08) as well as past influenza A (P=0.024) or B (P=0.006) infection were identified as predisposing factors for NMDAR-AB seropositivity. The >10% overall seroprevalence of NMDAR-AB of both healthy individuals and patients is unexpectedly high. Clinical significance, however, apparently depends on association with past or present perturbations of blood-brain barrier function. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Molecular Psychiatry is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=98712667
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/mp.2013.110
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 7
        StartPage: 1143
    Subjects:
      – SubjectFull: Psychoses
        Type: general
      – SubjectFull: Autoimmunity
        Type: general
      – SubjectFull: Autoimmune diseases
        Type: general
      – SubjectFull: Methyl aspartate receptors
        Type: general
      – SubjectFull: Schizophrenia treatment
        Type: general
      – SubjectFull: Blood-brain barrier disorders
        Type: general
    Titles:
      – TitleFull: Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood-brain barrier integrity.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Hammer, C
      – PersonEntity:
          Name:
            NameFull: Stepniak, B
      – PersonEntity:
          Name:
            NameFull: Schneider, A
      – PersonEntity:
          Name:
            NameFull: Papiol, S
      – PersonEntity:
          Name:
            NameFull: Tantra, M
      – PersonEntity:
          Name:
            NameFull: Begemann, M
      – PersonEntity:
          Name:
            NameFull: Sirén, A-L
      – PersonEntity:
          Name:
            NameFull: Pardo, L A
      – PersonEntity:
          Name:
            NameFull: Sperling, S
      – PersonEntity:
          Name:
            NameFull: Mohd Jofrry, S
      – PersonEntity:
          Name:
            NameFull: Gurvich, A
      – PersonEntity:
          Name:
            NameFull: Jensen, N
      – PersonEntity:
          Name:
            NameFull: Ostmeier, K
      – PersonEntity:
          Name:
            NameFull: Lühder, F
      – PersonEntity:
          Name:
            NameFull: Probst, C
      – PersonEntity:
          Name:
            NameFull: Martens, H
      – PersonEntity:
          Name:
            NameFull: Gillis, M
      – PersonEntity:
          Name:
            NameFull: Saher, G
      – PersonEntity:
          Name:
            NameFull: Assogna, F
      – PersonEntity:
          Name:
            NameFull: Spalletta, G
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 10
              Text: Oct2014
              Type: published
              Y: 2014
          Identifiers:
            – Type: issn-print
              Value: 13594184
          Numbering:
            – Type: volume
              Value: 19
            – Type: issue
              Value: 10
          Titles:
            – TitleFull: Molecular Psychiatry
              Type: main
ResultId 1